Iovance Biotherapeutics, INC Form 4 insider transactions

Frederick G. Vogt, Interim CEO & General Counsel of Iovance Biotherapeutics, reports the vesting of restricted stock units and subsequent withholding of shares for tax obligations.

Igor Bilinsky, COO of Iovance Biotherapeutics, reports the vesting of restricted stock units and subsequent withholding of shares for tax obligations.

Director Wendy L. Yarno acquired 25,000 deferred restricted stock units in Iovance Biotherapeutics, Inc. on March 1, 2024.

Wayne P. Rothbaum, a director of Iovance Biotherapeutics, acquired 100,000 deferred restricted stock units (DRSUs) on March 1, 2024, according to a recent SEC Form 4 filing.

Frederick G. Vogt, Interim CEO & General Counsel of Iovance Biotherapeutics, reports acquisition of restricted stock units.

Director Ryan D. Maynard acquired 50,000 deferred restricted stock units in Iovance Biotherapeutics, Inc. on March 1, 2024.

A Form 4 filing reveals that Iovance Biotherapeutics Director Michael Weiser acquired 100,000 deferred restricted stock units (DRSUs) on March 1, 2024.

Director Merrill A. McPeak acquired 50,000 deferred restricted stock units in Iovance Biotherapeutics, Inc. on March 1, 2024.

Director Iain D. Dukes reports acquisition of 100,000 deferred restricted stock units in Iovance Biotherapeutics, with vesting and issuance deferred under certain conditions.

Chief Medical Officer Friedrich Graf Finckenstein reports acquiring restricted stock units in Iovance Biotherapeutics.

Igor Bilinsky, Chief Operating Officer of Iovance Biotherapeutics, reported the acquisition of restricted stock units (RSUs) on March 1, 2024.

Jean-Marc Bellemin, CFO of Iovance Biotherapeutics, reports the acquisition of restricted stock units (RSUs) in the company.

Athena Countouriotis, a director at Iovance Biotherapeutics, acquired 50,000 deferred restricted stock units (DRSUs) on March 1, 2024, according to a recent SEC Form 4 filing.